Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
172
-
Total 13F shares, excl. options
-
81.4M
-
Shares change
-
-1.52M
-
Total reported value, excl. options
-
$209M
-
Value change
-
-$16.4M
-
Put/Call ratio
-
0.35
-
Number of buys
-
85
-
Number of sells
-
-79
-
Price
-
$2.57
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2024
228 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2024.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 172 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 81.4M shares
of 105M outstanding shares and own 77.76% of the company stock.
Largest 10 shareholders include Capital World Investors (13.9M shares), BlackRock Inc. (8.57M shares), FRANKLIN RESOURCES INC (6.26M shares), VANGUARD GROUP INC (5.99M shares), Palo Alto Investors LP (5.26M shares), Polar Capital Holdings Plc (3.57M shares), JPMORGAN CHASE & CO (2.94M shares), Stonepine Capital Management, LLC (2.8M shares), Rubric Capital Management LP (2.66M shares), and GEODE CAPITAL MANAGEMENT, LLC (2.3M shares).
This table shows the top 172 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.